December 31, 2019
2 min read

Stem cell therapy, FDA approvals lead 2019 ophthalmology news

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Ophthalmology news in 2019 included FDA approvals and breakthrough study results.

Here are the 10 most read articles of the year on

Phase 2a study shows improved vision with stem cell therapy for retinitis pigmentosa

Human retinal progenitor cell therapy from ReNeuron Group showed positive preliminary results in the company’s ongoing phase 1/2a clinical trial involving patients with retinitis pigmentosa. Read more.

Read follow-up reporting here.

FDA approves Alcon’s AcrySof IQ PanOptix trifocal IOL

PanOptix, which is already available in more than 70 countries, has been shown to deliver a combination of near, intermediate and distance vision while significantly reducing the need for glasses after surgery. Read more.

Watch follow-up reporting here.

Q&A: The rise of esports and its effect on vision

Esports is quickly becoming one of the most popular global pastimes to play and watch, with its estimated audience already surpassing that of Major League Baseball. Read more.

Teprotumumab for treatment of thyroid eye disease meets endpoints in phase 3 study

Results from the phase 3 OPTIC study showed more patients treated with teprotumumab had a meaningful improvement in proptosis compared with those who received placebo. Read more.

Read follow-up reporting here.

Upcoming pharmaceutical treatments for presbyopia may prevent, delay surgery

PRX 100 developed by Presbyopia Therapies could be the first pharmaceutical approach for presbyopic near vision correction and may be the first new treatment to go through the FDA for presbyopia correction, according to Richard L. Lindstrom, MD, at Hawaiian Eye 2019. Read more.

Read follow-up reporting here.

Protocol V trial results favor observation strategy for DME with good vision

The Protocol V clinical trial concludes that patients with center-involved diabetic macular edema and good vision can confidently be managed by observation, scheduling anti-VEGF injections only if vision deteriorates. Read more.

Novartis completes Alcon spin-off

Novartis shareholders were due to receive one Alcon share for every five Novartis shares. Read more.

Altaire issues large ophthalmic product recall

The products were recalled due to concerns regarding the manufacturing facility’s quality assurance controls. Read more.

Read follow-up reporting here.


LipiFlow more effective than warm compress for dry eye disease

The systematic review and meta-analysis consisted of 385 patients from four randomized controlled trials that compared the efficacy of a 12-minute vectored thermal pulsation treatment (LipiFlow, Johnson & Johnson Vision) vs. warm compress treatment. Read more.

FDA approves Rocklatan for open-angle glaucoma, ocular hypertension

A fixed-dose combination of netarsudil and latanoprost, Rocklatan — previously known as Roclatan — is designed to target the trabecular meshwork, which is considered the main cause of elevated IOP. Read more.

Read follow-up reporting here.